LVYE pharmaceutical released its performance in the first half of 2018: core products achieved double-digit growth, sales, R & D and M & a performance exceeded expectations

August 27, 2018 / Meitong news agency / -- green leaf Pharmaceutical Group (02186 HK) issued the performance announcement for the first half of 2018 on August 26 The financial report shows that the company's performance continues to show strong growth, and the core products have achieved double-digit growth, significantly higher than the industry level The company's R & D and listing of new drugs in global markets have been accelerated, and its international operation capacity has been further improved In the first half of 2018, LVYE pharmaceutical achieved sales revenue of RMB 2.204 billion, a year-on-year increase of 19.1%; the net profit attributable to shareholders reached RMB 563 million, a year-on-year increase of 46.1% The management of LVYE said: "with the joint efforts of global employees, LVYE achieved outstanding performance beyond the market expectation in the first half of 2018 Not only the existing products continue to show strong vitality, but also the follow-up product lines under research grasp policy opportunities to accelerate registration and application in China, the United States and other countries In addition, through M & A and cooperation, the company's product line competitiveness and commercial strength have been further improved, and it has taken a big step towards globalization We believe that the company will maintain the momentum of rapid development and make continuous breakthroughs in sales, R & D, M & A and other aspects " The highlights of performance in the first half of 2018 are as follows: products - achieve double-digit growth In the first half of 2018, all core products of the company achieved double-digit growth Among them, the rapid growth momentum of Lipitor, the rapid volume of benefit insurance policies such as Beixi, zhizhikang and himena, etc., and the proportion of contribution to the company's overall sales are increasing According to iqvia (original IMS) data, the growth rate of China's pharmaceutical industry in the first half of this year was only 2.84%, while that of green leaf pharmaceutical reached 12.14%, and its business performance significantly outperformed the industry average In terms of sales revenue, LVYE pharmaceutical has jumped from the top 20 domestic pharmaceutical companies at the end of 2017 to the top 15 In the second half of the year, the company expects that the competitive advantage of the products will be further consolidated and the market share is expected to continue to expand R & D -- accelerate the new drug listing cycle, lay out innovative product companies in depth and increase R & D investment The R & D investment in the first half of 2018 increased by 57.7% year-on-year With the strategy of independent R & D and external cooperation, LVYE pharmaceutical integrates global R & D resources, accelerates the R & D and marketing of new drugs, and has made remarkable achievements in the fields of innovative pharmaceutical preparations (NDDs), new molecular drugs (NCE) and biological antibodies In terms of innovative drug preparations (NDDs): risperidone sustained-release microspheres (ly03004) for the treatment of schizophrenia and bi-directional affective disorder have entered the final stage of application preparation of new drug marketing license (NDA), and will be applied in China and the United States; lotigotine sustained-release microspheres (ly03003) for the treatment of Parkinson's disease have been exempted from phase II clinical trials in China and the United States respectively, and entered phase III clinical trials; The treatment of mild to moderate Alzheimer's disease with carbartan multi day transdermal patch has entered a critical clinical stage In the aspect of new molecular drugs (NCE): the 1.1-class new drug for depression, anshufaxin sustained-release tablets (ly03005), has achieved positive results in the second phase of clinical trials in China; the new tumor immune drug, Ido / TDO double target inhibitor, ly01013, has been approved for clinical use; the new analgesic drug, ly03012, has also been declared for clinical use In terms of biological antibody, the bevacizumab analogues ly01008 for colorectal cancer and non-small cell lung cancer and ly06006 for postmenopausal women's osteoporosis entered the phase III and phase I clinical trials respectively, and the progress was smooth In addition, through a series of cooperative R & D projects, the company has actively arranged and developed in tumor immunotherapy, cell, gene therapy and other innovative fields In the first half of this year, the company has successively reached strategic cooperation with two U.S biotechnology companies, excelbiopharm LLC and elpisbiopharm, to jointly use in therapeutic antibody and car-t therapy projects of next-generation tumor immunotherapy M & A -- Strategic Synergy expands and global operation strength upgrades again The company entered into an agreement with AstraZeneca to acquire the business of sracom and sracom in 51 countries and regions around the world, so as to rapidly strengthen the global commercialization capacity in the field of central nervous system, and lay a solid foundation for the channel construction of the drugs to be listed in the global markets At the same time, the operation of the transdermal agent business acquired by the company at the end of 2016 is also very smooth, and the strategic synergy is constantly expanding Greenleaf's two subsidiaries in Germany and Switzerland have completed the acquisition of global rights to its contraceptive patch, apleek, with Bayer pharma In addition, a number of transdermal products have been successfully registered and listed in major new markets around the world, including Japan, Israel, Thailand, South Korea, Switzerland, etc.; buprenorphine patch, kabaratin patch and other products are also accelerating their introduction into China, starting local production and import registration, and will be officially declared soon Looking forward to the future, LVYE pharmaceutical management said with confidence: "we will, as always, adhere to the path of 'innovation' and 'internationalization', focus on the deep layout of the three strategic focuses of global R & D, global manufacturing and global market, increase our R & D investment in the technology fields with leading advantages and strategic focus, accelerate the global listing of new products, and better meet the needs Global patient needs " This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact with this website message, we will delete the content in the first time!